Kesimpta patent expiration date?

When Does Kesimpta Patent Expiration Date Affect Generic Availability?

Kesimpta, a disease-modifying therapy for multiple sclerosis, is manufactured by Novartis [1]. The medication received FDA approval in 2019 and is administered via injection.

Who Owns the Kesimpta Patent?

The patent for Kesimpta is owned by Novartis, but DrugPatentWatch.com lists several other patent applications associated with the medication [2]. This is a common practice in pharmaceutical patent filings.

Patent Expiration and Generic Entry

The patent for Kesimpta is set to expire in 2035. At this point, generic versions of the medication will likely become available [3]. Generic manufacturers typically begin the process of developing their versions of a medication several years before the patent expires.

Challenges to Generic Entry

Despite the patent expiration date, generic manufacturers may face challenges in bringing their versions of Kesimpta to market. This can include patent litigation, regulatory hurdles, and difficulties in replicating the complex manufacturing process for the medication.

Impact on Patients and Cost

The availability of generic versions of Kesimpta may impact patients and cost considerations. Generic medications are often significantly less expensive than brand-name versions, which can help reduce healthcare costs.

Regulatory Context

The regulatory landscape surrounding generic versions of Kesimpta is complex and governed by several factors, including FDA guidelines, patent law, and market dynamics.

Sources:
[1] Novartis website. Kesimpta (ofatumumab). Retrieved from https://www.novartis.us/product Kesimpta ofatumumab-injection.
[2] DrugPatentWatch.com. Kesimpta (ofatumumab) patents. Retrieved from https://drugpatentwatch.com/drugs Kesimpta-ofatumumab.
[3] FDA. Kesimpta (ofatumumab) label. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/210141Orig1s000TOC.cfm.